Organization
Developmental Therapeutics Branch
5 abstracts
Abstract
Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma.Org: James J. Peters VAMC, Genitourinary Malignancies Branch, NCI, National Institutes of Child Health and Human Development, Clinical Pharmacology Program,
Abstract
Tazemetostat in combination with topotecan and pembrolizumab in patients with recurrent small cell lung cancer.Org: Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA, Philadelphia, PA, National Cancer Center Hospital East, Kashiwa, Japan, Shinjuku-Ku, Japan,
Abstract
The role of innate immune system in modulating CHK1 inhibitor (CHK1i) response in BRCA wild-type (BRCAwt), platinum-resistant high-grade serous ovarian cancer (PR-HGSOC): Exploratory analysis from a phase II study of CHK1i prexasertib.Org: Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Bethesda, MD,
Abstract
Longitudinal follow-up and outcomes of pediatric and adult patients with SDH-deficient GIST.Org: Pediatric Oncology Branch, Clinical Center National Institutes of Health, Center for Cancer Research, National Cancer Institute, Surgical Oncology Program, Developmental Therapeutics Branch, National Cancer Institute, Vilnius, Lithuania,
Abstract
Analysis of systemic immune changes in patients with advanced cancer treated with immunotoxin LMB-100 and tofacitinib.Org: National Cancer Insititute, Developmental Therapeutics Branch, Nihon Medi-Physics, Epidemiology and Biostatistics, Thoracic and GI Malignancies Branch,